SCHEMBL5353441

SCHEMBL5353441

CC(=O)c1ccc(S(=O)(=O)N(C)CC(O)c2ccc(F)cc2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.45
HDAC4 P56524 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
KMT2A Q03164 5/20 0.41
POLB P06746 1/20 0.38
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP9 P14780 1/20 0.35
MMP8 P22894 1/20 0.35
MMP13 P45452 1/20 0.35
MMP14 P50281 1/20 0.35
MEN1 O00255 4/20 0.34
TP53 P04637 2/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 2/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5360893 0.85 AOC3 (0.46) AOC3HDAC4HDAC6KMT2APOLB
SCHEMBL5356409 0.83 KMT2A (0.56) AOC3KMT2APOLBMMP2MMP9
SCHEMBL5347924 0.78 KMT2A (0.47) AOC3HDAC4HDAC6KMT2APOLB
SCHEMBL5352834 0.76 RXFP1 (0.41) AOC3KMT2APOLBMEN1TP53
SCHEMBL5357039 0.75 AOC3 (0.37) AOC3KMT2AMEN1TP53LMNA
SCHEMBL5356011 0.73 AOC3 (0.36) AOC3GBA1
SCHEMBL5350418 0.73 AOC3 (0.35) AOC3TP53
SCHEMBL5361944 0.71 AOC3 (0.45) AOC3KMT2AMEN1LMNAMAPT
SCHEMBL5357321 0.70 HDAC4 (0.42) AOC3HDAC4HDAC6KMT2AMEN1
SCHEMBL5354253 0.69 LMNA (0.48) AOC3POLBTP53ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 AOC3 522/4885HDAC4 76/4885HDAC6 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.